Gyre Therapeutics, Inc. Recognition of Deferred Revenue
Gyre Therapeutics, Inc. (GYRE) reported Recognition of Deferred Revenue of $148.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2015-07-31
- Gyre Therapeutics, Inc. recognition of deferred revenue for the quarter ending 2014-12-31 was $0.00.
- Gyre Therapeutics, Inc. recognition of deferred revenue for the quarter ending 2014-09-30 was $25.00K.
- Gyre Therapeutics, Inc. recognition of deferred revenue for the quarter ending 2014-06-30 was $36.00K.
- Gyre Therapeutics, Inc. recognition of deferred revenue for the quarter ending 2014-03-31 was $87.00K, a 97.54% decline year-over-year.
- Gyre Therapeutics, Inc. recognition of deferred revenue for fiscal 2014 was $148.00K, a 95.81% decline from fiscal 2013.
- Gyre Therapeutics, Inc. recognition of deferred revenue for fiscal 2013 was $3.54M, a 93.89% decline from fiscal 2012.
- Gyre Therapeutics, Inc. recognition of deferred revenue for fiscal 2012 was $57.86M, a 40.62% decline from fiscal 2011.
- Gyre Therapeutics, Inc. recognition of deferred revenue for fiscal 2011 was $97.44M, a 16.32% increase from fiscal 2010.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 6 month | Recognition of Deferred Revenue 9 month | Recognition of Deferred Revenue 9 month as first filed | Recognition of Deferred Revenue 12 month |
|---|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $25.00K derived: sum of 2 quarters · filed 2015-03-16 | $61.00K derived: sum of 3 quarters · filed 2015-07-31 | $148.00K 10-K · filed 2015-03-16 | |
| 2014-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $61.00K derived: sum of 2 quarters · filed 2015-07-31 | $148.00K 10-Q · filed 2014-11-06 | $148.00K derived: sum of 4 quarters · filed 2015-07-31 | |
| 2014-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $123.00K 10-Q · filed 2015-07-31 | $123.00K derived: sum of 3 quarters · filed 2015-07-31 | $123.00K derived: sum of 4 quarters · filed 2015-07-31 | |
| 2014-03-31 | $87.00K 10-Q · filed 2015-05-07 | $87.00K derived: sum of 2 quarters · filed 2015-05-07 | $87.00K derived: sum of 3 quarters · filed 2015-05-07 | $87.00K derived: sum of 4 quarters · filed 2015-05-07 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $0.00 derived: sum of 2 quarters · filed 2015-03-16 | $0.00 derived: sum of 3 quarters · filed 2015-03-16 | $3.54M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $3.54M 10-Q · filed 2014-11-06 | $4.13M derived: sum of 4 quarters · filed 2015-03-16 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $3.54M 10-Q · filed 2014-08-07 | $4.13M derived: sum of 3 quarters · filed 2015-03-16 | $4.89M derived: sum of 4 quarters · filed 2015-03-16 | |
| 2013-03-31 | $3.54M 10-Q · filed 2014-05-08 | $4.13M derived: sum of 2 quarters · filed 2015-03-16 | $4.89M derived: sum of 3 quarters · filed 2015-03-16 | $38.54M derived: sum of 4 quarters · filed 2015-03-16 | |
| 2012-12-31 | $590.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $1.36M derived: sum of 2 quarters · filed 2015-03-16 | $35.00M derived: sum of 3 quarters · filed 2015-03-16 | $57.86M 10-K · filed 2015-03-16 | |
| 2012-09-30 | $768.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | $34.41M derived: sum of 2 quarters · filed 2013-11-06 | $57.27M 10-Q · filed 2013-11-06 | $52.27M 10-Q · filed 2012-11-08 | $76.22M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-06-30 | $33.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $56.50M 10-Q · filed 2013-08-07 | $75.45M derived: sum of 3 quarters · filed 2014-03-14 | $94.20M derived: sum of 4 quarters · filed 2014-03-14 | |
| 2012-03-31 | $22.86M 10-Q · filed 2013-05-08 | $41.80M derived: sum of 2 quarters · filed 2014-03-14 | $60.56M derived: sum of 3 quarters · filed 2014-03-14 | $81.30M derived: sum of 4 quarters · filed 2014-03-14 | |
| 2011-12-31 | $18.95M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $37.70M derived: sum of 2 quarters · filed 2014-03-14 | $58.45M derived: sum of 3 quarters · filed 2014-03-14 | $97.44M 10-K · filed 2014-03-14 | |
| 2011-09-30 | $18.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $39.50M derived: sum of 2 quarters · filed 2012-11-08 | $78.49M 10-Q · filed 2012-11-08 | $100.32M derived: sum of 4 quarters · filed 2013-03-15 | |
| 2011-06-30 | $20.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $59.74M 10-Q · filed 2012-08-09 | $81.57M derived: sum of 3 quarters · filed 2013-03-15 | $103.35M derived: sum of 4 quarters · filed 2013-03-15 | |
| 2011-03-31 | $38.99M 10-Q · filed 2012-05-09 | $60.82M derived: sum of 2 quarters · filed 2013-03-15 | $82.61M derived: sum of 3 quarters · filed 2013-03-15 | ||
| 2010-12-31 | $21.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $43.61M derived: sum of 2 quarters · filed 2013-03-15 | $83.77M 10-K · filed 2013-03-15 | ||
| 2010-09-30 | $21.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | $61.94M 10-Q · filed 2011-11-03 | |||
| 2010-06-30 | $40.15M 10-Q · filed 2011-08-09 | ||||
| 2009-12-31 | $6.38M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |